Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
3.55 p
0.24 p(5.04%)
At close: 4:00 PM EST
3.55 p
0.24 p(5.04%)
Day’s Range― - ―
52-Week Range2.40 p - 5.20 p
Previous CloseN/A
Volume846.29K
Average Volume (3M)1.12M
Market Cap
£33.49M
Enterprise Value26.13M
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ReadinessMHRA approval plus site/CRO setup and J&J supplying teclistamab positions TOPICAL to enroll rapidly and deliver an interim readout in summer 2026. Operational readiness materially reduces execution risk, accelerates clinical validation and strengthens near‑term partner engagement prospects.
Robust Translational Efficacy Signal (LPS Model)Strong, dose‑dependent cytokine suppression in a controlled human LPS challenge demonstrates clear target engagement and biological plausibility for CRS prevention. This durable biological signal raises the probability that clinical effects will translate to patients and improves attractiveness to partners ahead of pivotal work.
Low Leverage / No Reported DebtA debt‑free capital structure lowers fixed financing costs and downside bankruptcy risk, preserving strategic optionality for licensing, partnerships or M&A. For a development‑stage biotech, this improves negotiability with partners and reduces cash‑flow sensitivity to interest rate moves.
Bears Say
Limited Cash Runway & Ongoing BurnYear‑end cash of £7.7m and runway into 2027 contrast with sustained operating outflows (~£4.5m annually), forcing near‑term fundraising or partnering. This elevates dilution and execution risk, as material follow‑on trials or commercialization activities will require external capital within the planning horizon.
Pre‑revenue With Persistent LossesBeing pre‑revenue with multi‑year net losses (~£3.9m–£5.8m) means the company cannot self‑fund development or operations from product cash flow. Long‑term value therefore depends on successful trials and external financing, extending time to sustainable margins and increasing binary risk for investors.
Dependence On External Partners For Late‑stage WorkRelying on external partners for late‑stage development and commercialization reduces control over clinical strategy, timing and economics. Partner negotiations will determine downstream returns and can delay programs if counterpart priorities shift, creating execution and monetization risk independent of clinical success.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.40 p and its highest was 5.20 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £33.49M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 111 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
-55.47%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---